Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Merkel Cell Carcinoma (Aug 2019)

Posted by Matt Breese on Aug 2, 2019

Find me on:

According to our recent payer coverage analysis for Merkel cell carcinoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for Merkel cell carcinoma treatments shows that under the pharmacy benefit, about 27% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Merkel Cell Carcinoma_2Q2019Data snapshot as of Q2 2019

Trends: In December 2018, the FDA gave accelerated approval to Keytruda (pembrolizumab) for use in adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.    

To read the full Reality Check on Merkel Cell Carcinoma treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing